Target Name: MLXIPL
NCBI ID: G51085
Review Report on MLXIPL Target / Biomarker Content of Review Report on MLXIPL Target / Biomarker
MLXIPL
Other Name(s): bHLHd14 | Williams-Beuren syndrome chromosome region 14 protein 1 | WS basic-helix-loop-helix leucine zipper protein | Class D basic helix-loop-helix protein 14 | ChREBP | carbohydrate response element binding protein | MLXIPL variant 1 | MLX interacting protein like, transcript variant 1 | Williams Beuren syndrome chromosome region 14 | Mlx interactor | MLX | class D basic helix-loop-helix protein 14 | MONDOB | MIO | Williams-Beuren syndrome chromosomal region 14 protein | Williams-Beuren syndrome chromosome region 14 protein 2 | MLX interactor | williams-Beuren syndrome chromosomal region 14 protein | Williams-Beuren syndrome chromosome region 14 protein 3 | CHREBP | MLXPL_HUMAN | Carbohydrate-responsive element-binding protein (isoform alpha) | WS-bHLH | MLX-interacting protein-like | MLX interacting protein like | Carbohydrate-responsive element-binding protein | WBSCR14

MLXIPL: A Versatile Protein with Multiple Functions

MLXIPL (bHLHd14) is a protein that is expressed in various tissues throughout the body. It is a member of the HIghly conserved non-coding RNA (ncRNA) family, which is characterized by the presence of a conserved intron-exon boundary and a conserved positive selection mark (唯) in the 5' end. MLXIPL is expressed in a variety of tissues, including the brain, heart, and liver, and has been shown to play a role in various biological processes, including cell signaling, inflammation, and metabolism.

One of the unique features of MLXIPL is its ability to interact with other proteins. It has been shown to form a complex with the protein PDGF-BB, which is a key signaling molecule in the process of platelet function and blood clotting. This interaction between MLXIPL and PDGF-BB has been shown to play a role in the regulation of platelet aggregation and the formation of blood clots.

Another interesting property of MLXIPL is its ability to interact with the protein TCF-1, which is a transcription factor that plays a central role in the regulation of cell growth and differentiation. This interaction between MLXIPL and TCF-1 has been shown to play a role in the regulation of cellular processes such as cell proliferation, migration, and invasion.

In addition to its interactions with PDGF-BB and TCF-1, MLXIPL has also been shown to interact with the protein p53, which is a well-known tumor suppressor protein that plays a critical role in the regulation of cell growth and apoptosis. This interaction between MLXIPL and p53 has been shown to play a role in the regulation of tumorigenesis and the response to external stressors such as chemotherapy and radiation therapy.

MLXIPL has also been shown to play a role in the regulation of inflammation. It has been shown to interact with the protein NF-kappa-B, which is a signaling molecule that plays a central role in the regulation of inflammation and immune responses. This interaction between MLXIPL and NF-kappa-B has been shown to play a role in the regulation of inflammatory responses and the development of inflammatory diseases.

In conclusion, MLXIPL is a protein that has been shown to play a variety of roles in various biological processes. Its ability to interact with other proteins and its unique expression patterns across different tissues make it an attractive drug target and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of MLXIPL in these biological processes and to develop effective treatments for these diseases.

Protein Name: MLX Interacting Protein Like

Functions: Transcriptional repressor. Binds to the canonical and non-canonical E box sequences 5'-CACGTG-3' (By similarity)

The "MLXIPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLXIPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3 | MOG | MOGAT1 | MOGAT2 | MOGAT3 | MOGS | MOK | MON1A | MON1B | MON2 | Monoamine oxidase (MAO) | Monoamine Transporter (MAT) | MORC1 | MORC2 | MORC2-AS1 | MORC3 | MORC4 | MORF4 | MORF4L1 | MORF4L1P1 | MORF4L1P3 | MORF4L1P7 | MORF4L2 | MORF4L2-AS1 | MORN1 | MORN2 | MORN3 | MORN4 | MORN5 | MOS | MOSMO